vs
BIOMERICA INC（BMRA）与Cardio Diagnostics Holdings, Inc.（CDIO）财务数据对比。点击上方公司名可切换其他公司
BIOMERICA INC的季度营收约是Cardio Diagnostics Holdings, Inc.的340.4倍（$1.2M vs $3.6K）。Cardio Diagnostics Holdings, Inc.同比增速更快（-21.2% vs -26.0%）。过去两年BIOMERICA INC的营收复合增速更高（9.1% vs -52.8%）
Biomerica Inc.是一家全球性医疗技术企业，研发、生产及销售诊断检测试剂盒与相关医疗产品，产品线覆盖胃肠疾病、传染病、食物不耐受检测及即时检测解决方案，服务全球多地的临床实验室、医疗机构及零售医疗客户。
Cardio Diagnostics Holdings, Inc.是一家专注于精准心血管医疗的企业，开发并商业化整合遗传与表观遗传技术的诊断检测产品，可早期识别冠心病、心力衰竭等心血管疾病，主要服务美国市场的医疗机构、临床实验室与患者。
BMRA vs CDIO — 直观对比
营收规模更大
BMRA
是对方的340.4倍
$3.6K
营收增速更快
CDIO
高出4.8%
-26.0%
两年增速更快
BMRA
近两年复合增速
-52.8%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $3.6K |
| 净利润 | $-1.3M | — |
| 毛利率 | 4.2% | — |
| 营业利润率 | -113.5% | — |
| 净利率 | -109.1% | — |
| 营收同比 | -26.0% | -21.2% |
| 净利润同比 | -38.9% | 3.6% |
| 每股收益（稀释后） | $-0.45 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRACDIO
| Q4 25 | $1.2M | $3.6K | ||
| Q3 25 | $1.4M | $2.9K | ||
| Q2 25 | $749.0K | $7.5K | ||
| Q1 25 | $1.1M | $940 | ||
| Q4 24 | $1.6M | $4.5K | ||
| Q3 24 | $1.8M | $6.6K | ||
| Q2 24 | $1.1M | $7.9K | ||
| Q1 24 | $1.0M | $15.9K |
净利润BMRACDIO
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $2.0K | $-1.7M | ||
| Q2 25 | $-1.5M | $-1.7M | ||
| Q1 25 | $-1.2M | $-1.6M | ||
| Q4 24 | $-950.0K | — | ||
| Q3 24 | $-1.3M | $-1.4M | ||
| Q2 24 | $-1.4M | $-1.3M | ||
| Q1 24 | $-1.9M | $-4.2M |
毛利率BMRACDIO
| Q4 25 | 4.2% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | -33.0% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | 16.0% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -14.7% | — |
营业利润率BMRACDIO
| Q4 25 | -113.5% | — | ||
| Q3 25 | -81.0% | -59950.9% | ||
| Q2 25 | -209.1% | -22457.5% | ||
| Q1 25 | -108.1% | -173463.8% | ||
| Q4 24 | -60.7% | — | ||
| Q3 24 | -75.7% | -21412.9% | ||
| Q2 24 | -136.6% | -16295.6% | ||
| Q1 24 | -196.7% | -26105.3% |
净利率BMRACDIO
| Q4 25 | -109.1% | — | ||
| Q3 25 | 0.1% | -60053.8% | ||
| Q2 25 | -206.1% | -22517.7% | ||
| Q1 25 | -103.9% | -173943.0% | ||
| Q4 24 | -58.1% | — | ||
| Q3 24 | -72.8% | -21467.6% | ||
| Q2 24 | -127.1% | -16365.9% | ||
| Q1 24 | -188.6% | -26140.0% |
每股收益（稀释后）BMRACDIO
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $0.00 | $-0.98 | ||
| Q2 25 | $-0.99 | $-0.97 | ||
| Q1 25 | $-0.48 | $-0.97 | ||
| Q4 24 | $-0.06 | — | ||
| Q3 24 | $-0.63 | $-1.73 | ||
| Q2 24 | $-2.57 | $-1.71 | ||
| Q1 24 | $-0.11 | $-5.93 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.4M | $7.0M |
| 总资产 | $6.0M | $7.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRACDIO
| Q4 25 | $2.5M | — | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | $3.1M | — | ||
| Q1 25 | $3.1M | — | ||
| Q4 24 | $2.4M | — | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $4.2M | — | ||
| Q1 24 | $5.3M | — |
股东权益BMRACDIO
| Q4 25 | $4.4M | $7.0M | ||
| Q3 25 | $5.2M | $8.2M | ||
| Q2 25 | $4.1M | $9.7M | ||
| Q1 25 | $5.5M | $11.4M | ||
| Q4 24 | $5.1M | $9.6M | ||
| Q3 24 | $5.3M | $3.7M | ||
| Q2 24 | $6.6M | $3.1M | ||
| Q1 24 | $7.8M | $3.0M |
总资产BMRACDIO
| Q4 25 | $6.0M | $7.8M | ||
| Q3 25 | $6.9M | $8.8M | ||
| Q2 25 | $5.9M | $10.4M | ||
| Q1 25 | $7.4M | $12.3M | ||
| Q4 24 | $7.3M | $10.6M | ||
| Q3 24 | $7.9M | $4.5M | ||
| Q2 24 | $9.3M | $4.0M | ||
| Q1 24 | $10.3M | $4.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-991.0K | $-5.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-5.9M |
| 自由现金流率自由现金流/营收 | — | -166361.5% |
| 资本支出强度资本支出/营收 | — | 5269.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-10.5M |
8季度趋势，按日历期对齐
经营现金流BMRACDIO
| Q4 25 | $-991.0K | $-5.7M | ||
| Q3 25 | $-268.0K | $-1.4M | ||
| Q2 25 | $-661.0K | $-1.6M | ||
| Q1 25 | $-1.0M | $-1.4M | ||
| Q4 24 | $-791.0K | $-5.0M | ||
| Q3 24 | $-1.3M | $-1.2M | ||
| Q2 24 | $-1.0M | $-1.2M | ||
| Q1 24 | $-1.8M | $-1.2M |
自由现金流BMRACDIO
| Q4 25 | — | $-5.9M | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | $-1.6M | ||
| Q1 25 | — | $-1.4M | ||
| Q4 24 | — | $-5.2M | ||
| Q3 24 | — | $-1.2M | ||
| Q2 24 | $-1.1M | $-1.4M | ||
| Q1 24 | — | $-1.3M |
自由现金流率BMRACDIO
| Q4 25 | — | -166361.5% | ||
| Q3 25 | — | -54509.7% | ||
| Q2 25 | — | -21273.1% | ||
| Q1 25 | — | -149562.6% | ||
| Q4 24 | — | -115422.6% | ||
| Q3 24 | — | -17942.3% | ||
| Q2 24 | -95.5% | -17513.3% | ||
| Q1 24 | — | -7866.9% |
资本支出强度BMRACDIO
| Q4 25 | — | 5269.1% | ||
| Q3 25 | — | 5703.5% | ||
| Q2 25 | — | 250.1% | ||
| Q1 25 | — | 615.6% | ||
| Q4 24 | — | 4759.9% | ||
| Q3 24 | — | 353.3% | ||
| Q2 24 | 2.1% | 2133.4% | ||
| Q1 24 | 0.0% | 125.5% |
现金转化率BMRACDIO
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
